Sentient announces that the U.S. Food and Drug Administration has approved Tixel by Sentient, its non-invasive skin resurfacing technology, for the treatment of periorbital wrinkles.
Periorbital wrinkles, commonly known as “crow’s feet,” are fine lines that appear around and under the eyes, representing one of the earliest signs of aging. These wrinkles can be particularly challenging to treat since the skin around the eyes is thinner and more delicate compared to the rest of the face.
Tixel by Sentient delivers short bursts of thermal energy into the skin’s surface without damaging the deeper tissues. The device combines heat with the forward motion of a medical-grade titanium tip. When briefly applied to the skin, the device transfers thermal energy directly to its top layers, creating controlled micro-damage that stimulates collagen production and rejuvenates the skin’s appearance.
Moreover, Tixel by Sentient does not emit radiation, eliminating the need for laser-impenetrable metal ocular shields or eye shields typically used during laser treatments to protect sensitive areas, making the treatment process simpler and more comfortable for patients. Makeup can be applied the day after treatment, and pain and social downtime are minimal compared to laser and radio frequency treatments.
“The FDA’s approval for treating periorbital wrinkles with Tixel by Sentient is a game-changer for patients and for the aesthetics industry,” says Chris Cella, CEO of Sentient. “It reaffirms Sentient’s dedication to innovation and delivering safe and effective outcomes for our patients. We look forward to continuing our mission of enhancing beauty and boosting confidence with our advanced aesthetic care technologies.”
Tixel by Sentient has been used in Europe since 2011 and received FDA clearance for skin resurfacing of all skin types two years ago.